Document DGa0jjZeaLmRX0RmvjvqNaxK5

3M Specialty Materials 3M Center St. Paul, MN 55144-1000 651 733 1110 P-1 3M May 17, 2007 L Document Control Office Docket AR-226 EPA East Building, Room 6428 1201 Constitution Avenue, N.W. Washington, DC 20460 Phone: 202-564-8930 Attention: OPPT Docket No. AR-226 (Mary Dominiak - Room 4410) ' 7 ' Re: Information on Perfluorooctane Sulfonate, Perfluorooctanoic Acid, and Related Compounds Dear Ms. Dominiak: One of the documents in our May 10, 2007 submission contained some copying errors. Please substitute the enclosed good copy of the Final Report and Appendix, "The Effect of 3 Perfluorinated Alkyl Sulphonated on Cholesterol/Bile Acid Metabolism in 15%-Fat Fed E3Leiden Trangenic Mice In Vivo and on Fatty Acid Conversion into Cholesterol in Rat Hepatocytes In Vitro" for the copy previously submitted. The study is not confidential. Thank you very much for your assistance. Very truly yours, cc: Dr. Jennifer Seed Mr. John Line Stine, MDH Mr. James Kelly, MDH Dr. Helen Goeden, MDH (with enclosure) Michael A. Santoro Director of Environmental Health Safety and Regulatory Affairs 3M Center, Building 236-IB-10 St. Paul, MN 55144 651-733-6374 (phone) 651-733-1958 (fax) E-mail: masantoro@.mmm.com CONTAINS NO CBI / no :,'f TNO-report ;-v. r p . - i P-2n r The effec t o f 3 P erfluorinated A lkyl SULPHONATED ON CHOLESTEROL/BILE ACID METABOLISM IN 15 %-FAT FED E3-LEIDEN T r a n s g e n ic m ic e In Vivo a n d o n f a t t y a c id CONVERSION INTO CHOLESTEROL IN RAT h e p a t o c y t e s In Vitro. Project / study number 031.10074 / 3M-02 TNO Quality of Life TNO Biosciences Gaubius laboratory Zrnikedreef9, P.O.3ox 2215 2301 CE Leiden The Netherlands Phone+31 71 5181209 Fax +31 71 518 1901 Authors: L.H. Cohen E.J. Peterman E. Hoegee-de Nobel In assignment oh. 3M, Medical Department Study monitor John L. Butenboff, Ph.D.. CIH. DABT Corporate Scientist Medical Department 3M Center, BuHding 0220-02-E-02 SLPaul, Minnesota 55144-1000 USA Phone: +1.651.733.1962 Fax: +1.651.733.1773 E-mail: ilbuenhoff@rnmni.ccm Study director Dr. louts H. Cohen Status and Date: Final version: 04 December 2006 Previous versions: Drafd: 18 October2006 Draft2: 30 October 20C6 Draft3: 28 November 2006 Num ber of pages: 35 Authorization by Dr. P .H A Quax, Technology manager of Vascular and Metabolic Diseases; Signature and date: Al " f \ J- ( ' of Ibl 0 1 of 35 CONTAINS NO CB1 o? 3M Specialty Materials 3M Center St. Paul, MN 55144-1000 651 733 1110 p.3 c May 8, 2007 Document Control Office Docket AR-226 EPA East Building, Room 6428 1201 Constitution Ave., N.W. Washington, DC 20460 Phone: 202-564-8930 Attention: OPPT Docket No. AR-226 (Mary Dominiak - Room 4410) Re: Information on Perfluorooctane Sulfonate, Perfluorooctanoic Acid, and Related Compounds Dear Ms. Dominiak: This continues 3M's voluntary submissions of data on perfluorooctane sulfonate (PFOS), perfluorooctanoic acid (PFOA), and related compounds. We are enclosing paper copies of the following: Final Report and Appendix, "The Effect of 3 Perfluorinated Alkyl Sulphonates on Cholesterol/Bile Acid Metabolism in 15%-Fat Fed E3-Leiden Transgenic Mice In Vivo and on Fatty Acid Conversion into Cholesterol in Rat Hepatocytes In Vitro." TNO Quality of Life, TNO Biosciences. December 4, 2006. Apelberg, Benjamin Joseph, "Fetal Exposure to Perfluorinated Compounds: Distribution and Determinants of Exposure and Relationships with Weight and Size at Birth," dissertation submitted to Johns Hopkins University (Lynn Goldman, thesis adviser), August 2006 (publicly available at Proquest.com dissertation service). Two DuPont documents produced to 3M by plaintiffs in litigation referencing retiree half-life data which corroborate 3M's retiree half-life study: o Playtis, A.J. "Washington Works C-8 Industrial Hygiene," 6/30/99 [half-life data is on the page stamped EID510286]; and o Playtis, A.J. E-mail to G.W. Jepson, et al., Re: Pensioner Blood Data, 8/8/00. We also note that in a letter to the docket and agency officials dated February 2, 2007, Robert A. Bilott, counsel for Plaintiffs in civil litigation in Washington County, Minnesota (.Palmer, et al. v. 3M), provided information regarding levels of perfluorochemicals in the blood 3 0^52- P-4 serum of fifteen individuals in Minnesota. However, it appears ten of the samples submitted with the letter had already been submitted with prior letters: SAMPLE NO. L7652-25 L7652-27 L7932-1 L7932-2 L7932-28 L7932-39 L7932-51 L7932-52 L7932-53 L7932-54 SUBMISSION TO THE DOCKET May 12, 2005 letter from Mr. Bilott May 12, 2005 letter from Mr. Bilott October 20, 2005 letter from Mr. Bilott October 20, 2005 letter from Mr. Bilott October 20, 2005 letter from Mr. Bilott October 20, 2005 letter from Mr. Bilott October 20, 2005 letter from Mr. Bilott October 20, 2005 letter from Mr. Bilott October 20, 2005 letter from Mr. Bilott October 20, 2005 letter from Mr. Bilott Please feel free to contact me with any questions. Very truly yours, Enclosures cc: Dr. Jennifer Seed Mr. John Line Stine, MDH Mr. James Kelly, MDH Dr. Helen Goeden, MDH Director of Environmental Health Safety and Regulatory Affairs 3M Center, Building 236-IB-10 St. Paul, MN 55144 651-733-6374 (phone) 651-733-1958 (fax) E-mail: masantoro@mmm.com 4